{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:39:59Z","timestamp":1782401999305,"version":"3.54.5"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome caused by pathogenic variants in the <jats:italic>NF1<\/jats:italic> gene, encoding a multidomain inhibitor of Ras activity. Thus, NF1 is considered a RASopathy and drugs targeting the RAS\/mitogen-activated protein kinase (MAPK) pathway, such as the MAP kinase (MEK) 1\/2 inhibitor Selumetinib, are promising therapeutic options to treat NF1-associated tumors, especially plexiform neurofibromas and optic way gliomas. However, surgical treatment is often required for NF1-related cerebrovascular manifestations, such as moyamoya syndrome (MMS). We report a case of an 8-year-old patient receiving Selumetinib at the dose of 25\u2005mg\/m2 orally 2 times a day as a treatment for many plexiform neurofibromas. He suffered from two close strokes and brain MRI revealed a severe cerebral vasculopathy consistent with MMS, with marked stenosis of both the internal carotid arteries. A two-step surgical revascularization procedure was performed, consisting of a direct by-pass with an encephalo-mio-synangiosis (EMS) followed by encephalo-duro-arterio-synangiosis (EDAS). Surprisingly, despite the surgical technical success, follow-up MRI revealed lack of the expected revascularization. Selumetinib is a powerful therapeutic option in the treatment of severe NF1-related tumors. However, our findings suggest that this drug may interfere with cerebral neovascularization in patients with MMS requiring surgical revascularization. This is supported by the crucial role of the Vascular-Endothelial Growth Factor (VEGF), whose signaling pathway involve MAPK, as promoter of the neovascularization. Our observations suggest to adopt an imaging surveillance strategy to prevent unfavorable surgical outcome in patients with NF1-associated MMS receiving Selumetinib, and that priority should be given to surgical revascularization.<\/jats:p>","DOI":"10.3389\/fped.2023.1051026","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T08:00:15Z","timestamp":1677484815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case report: Revascularization failure in NF1-related moyamoya syndrome after selumetinib: A possible pathophysiological correlation?"],"prefix":"10.3389","volume":"11","author":[{"given":"Cristina","family":"Chelleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Ognibene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasavina","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pavanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/cancers13081879","article-title":"Genotype-Phenotype correlations in neurofibromatosis type 1: a single-center cohort study","volume":"13","author":"Scala","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00381-018-3833-7.","article-title":"When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience","volume":"34","author":"Scala","year":"2018","journal-title":"Childs Nerv Syst"},{"key":"B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK Inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a pediatric brain tumor consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1212\/WNL.0000000000013296","article-title":"Efficacy and safety of\u00a0selumetinib in pediatric patients with neurofibromatosis type 1: a systematic review and meta-analysis","volume":"98","author":"Hwang","year":"2022","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s0092-8674(00)81872-3","article-title":"Oncoprotein networks","volume":"88","author":"Hunter","year":"1997","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK And the inhibitors: from bench to bedside","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B16","article-title":"Neurofibromatosis 1. 1998 [updated 2022 Apr 21]","author":"Friedman","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/0883073812448531","article-title":"Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1","volume":"28","author":"Kaas","year":"2013","journal-title":"J Child Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1212\/01.WNL.0000150544.00016.69","article-title":"Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1","volume":"64","author":"Rosser","year":"2005","journal-title":"Neurology"},{"key":"B19","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom J Morphol Embryol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10143-021-01596-0","article-title":"Imaging methods for surgical revascularization in patients with moyamoya disease: an updated review","volume":"45","author":"Du","year":"2022","journal-title":"Neurosurg Rev"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1051026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T15:39:10Z","timestamp":1679931550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1051026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":20,"alternative-id":["10.3389\/fped.2023.1051026"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1051026","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"article-number":"1051026"}}